E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
ViroPharma,'s adjusted earnings per share data for the three months ended in Sep. 2013 was €0.045. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.39 for the trailing ten years ended in Sep. 2013.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
The historical data trend for ViroPharma,'s E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ViroPharma,'s Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroPharma,'s Shiller PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ViroPharma,'s Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where ViroPharma,'s Shiller PE Ratio falls into.
ViroPharma, E10 Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, ViroPharma,'s adjusted earnings per share data for the three months ended in Sep. 2013 was:
Add all the adjusted EPS together and divide 10 will get our e10.
ViroPharma, (FRA:VPH) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
ViroPharma,'s Shiller P/E Ratio of today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
ViroPharma, E10 Related Terms
Thank you for viewing the detailed overview of ViroPharma,'s E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:VPH has been successfully added to your 